Evidence map›Paper›PMID 40709054›Full record

ArticleBreast cancer (Dove Medical Press)2025

Peripheral TNF-α and CD8

Jiangping Wu, Xin Ou, Keyu Yuan, Feng Shi, Quan Zhou, Suzhen Lyu, Yanping Li, Yanjie Zhao, Yu Cao, Jianping Sun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiangping Wu *Center of Clinical Epidemiology and Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People's Republic of China.
Xin Ou *Center of Clinical Epidemiology and Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People's Republic of China.
Keyu YuanDepartment of Breast Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.
Feng ShiDepartment of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.ORCID 0000-0002-1850-7796
Quan ZhouDepartment of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, People's Republic of China.
Suzhen LyuDepartment of Breast Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.
Yanping LiDepartment of Breast Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.
Yanjie ZhaoDepartment of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.ORCID 0000-0003-0831-6395
Yu CaoCenter of Clinical Epidemiology and Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People's Republic of China.
Jianping SunCenter of Clinical Epidemiology and Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People's Republic of China.ORCID 0000-0001-8649-7377
Qingkun SongCenter of Clinical Epidemiology and Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People's Republic of China.ORCID 0000-0002-1159-257X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Programmed death-ligand 1 (PD-L1) is an immunotherapy target; however, its detection is based on biopsy tissues, and repeated biopsies present clinical challenges. This study aimed to explore peripheral blood-based alternatives to PD-L1 tissue detection in breast cancer (BC), particularly stratification by neoadjuvant therapy (NAT). Methods: A total of 134 cases were recruited, the peripheral lymphocyte subtypes and cytokines were detected by flow cytometry and PD-L1 expression in tumor microenvironment (TME) was detected by immunohistochemistry and assessed by two qualified pathologists. Results: The patients with positive PD-L1 expression had peripheral CD8 Conclusion: Peripheral CD8

Indexed as

breast cancercytokineneoadjuvant therapyprogrammed death-ligand 1T lymphocyte subtype

Identifiers

PMID40709054
PMCPMC12288228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.